Results 11 to 20 of about 7,708 (214)
Prolactinoma presenting as chronic anaemia with osteoporosis: a case report [PDF]
Journal of Medical Case Reports, 2010 Introduction Unexplained anaemia is a rare mode of presentation for prolactinoma. We describe a case of a man, with chronic anaemia ascribed to old age.
Hanley John P, MacLean Fergus R
doaj +3 more sources
Anti-c-myc efficacy block EGFL7 induced prolactinoma tumorigenesis
Open Chemistry, 2019 Resistance to Dopamine agonists therapy is still a key factor that hinders the clinical treatment of prolactinoma. Consequently, a large number of investigations have been carried out to identify novel therapeutic targets.
Lan Xiaolei +4 more
doaj +2 more sources
Late presentation of acromegaly in medically controlled prolactinoma patients
Endocrinology, Diabetes & Metabolism Case Reports, 2016 Co-secretion of growth hormone (GH) and prolactin (PRL) from a single pituitary adenoma is common. In fact, up to 25% of patients with acromegaly may have PRL co-secretion.
Ekaterina Manuylova +6 more
doaj +2 more sources
Clinical characteristics and presence of prolactinoma in women with hyperprolactinemia
Iatreia, 2016 Objectives: To clinically characterize women with hyperprolactinemia at InSer Pereira (Colombia) and to determine the prevalence of prolactinoma. Methods: Retrospective description of 45 patients with hyperprolactinemia, and contrasted pituitary magnetic
López-Clavijo, Carlos Alberto +3 more
doaj +2 more sources
Evaluation of Hyperandrogenemia in Women with Prolactinoma
Endocrinology Research and Practice, 2020 Objective: Differential diagnosis of androgen excess disorders revealed the occurrence of hyperprolactinemia. However, an elevated level of prolactin (hyperprolactinemia) is a very infrequent cause of hyperandrogenemia in clinical practice.
Mehmet Çağrı ÜNAL +3 more
doaj +2 more sources
Prevalence of Autoimmune Thyroiditis and Other Autoimmune Diseases in Relation to Serum BAFF/APRIL Levels in Prolactinoma Patients [PDF]
Gazi Medical JournalObjective: There may be an association between hyperprolactinemia and autoimmune diseases, possibly because of the immunostimulatory effect of prolactin.
Özlem Kanburoğlu Meletli +8 more
doaj +2 more sources
Trials, 2021 Background First-line treatment for prolactinomas is a medical treatment with dopamine agonists (DAs), which effectively control hyperprolactinaemia in most patients, although post-withdrawal remission rates are approximately 34%.
Ingrid M. Zandbergen +23 more
doaj +2 more sources
Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole [PDF]
Endocrinology, Diabetes & Metabolism Case Reports, 2016 In this report, we describe a female patient with both prolactinoma and psychotic disorder who was successfully treated with aripiprazole, a partial dopamine 2 receptor agonist.
Ilse C A Bakker +2 more
doaj +2 more sources
Przeglad lekarski, 2009 Prolactin-secreting tumours (prolactinomas) are benign neoplasms constituting about 40 percent of all pituitary tumours. The incidence of these tumours varies with age and sex, occurring most frequently in females between 20 and 40-years-old. The clinical symptoms of prolactinomas are menstrual dysfunction and galactorrhea in women and loss of libido ...
Robert, Krysiak +3 more
openaire +2 more sources
La Presse Médicale, 2021 Hyperprolactinemia, defined by a level of serum prolactin above the standard upper limit of normal range, is a common finding in clinical practice and prolactinomas are the main pathological cause. Prolactinomas lead to signs and symptoms of hormone oversecretion, such as galactorrhea and hypogonadism, as well as symptoms of mass effect, including ...
Luiz Eduardo Wildemberg +2 more
openaire +2 more sources